Close

Five Prime Therapeutics (FPRX) PT Raised to $31 at BMO Capital

March 18, 2015 8:26 AM EDT Send to a Friend
BMO Capital analyst Jim Birchenough reiterated an Outperform rating and boosted his price target on Five Prime Therapeutics (NASDAQ: FPRX) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login